Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations
Hiroshi Miyata, Tappei Takada, Yu Toyoda, et al.
Frontiers in Pharmacology (2016) Vol. 7
Open Access | Times Cited: 123

Showing 1-25 of 123 citing articles:

Physiology of Hyperuricemia and Urate-Lowering Treatments
Caroline Benn, Vivek Dua, Rachel Gurrell, et al.
Frontiers in Medicine (2018) Vol. 5
Open Access | Times Cited: 273
Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters
Andaleeb Sajid, Hadiar Rahman, Suresh V. Ambudkar
Nature reviews. Cancer (2023) Vol. 23, Iss. 11, pp. 762-779
Closed Access | Times Cited: 78
Inhibitors of Human ABCG2: From Technical Background to Recent Updates With Clinical Implications
Yu Toyoda, Tappei Takada, Hiroshi Suzuki
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 128
The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion
Kazi Mirajul Hoque, Eryn E. Dixon, Raychel M. Lewis, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 114
Effect and mechanism of dioscin from Dioscorea spongiosa on uric acid excretion in animal model of hyperuricemia
Yi Zhang, Lijun Jin, Jinchang Liu, et al.
Journal of Ethnopharmacology (2017) Vol. 214, pp. 29-36
Closed Access | Times Cited: 90
Structures of ABCG2 under turnover conditions reveal a key step in the drug transport mechanism
Qin Yu, Dongchun Ni, Julia Kowal, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 74
Function of Uric Acid Transporters and Their Inhibitors in Hyperuricaemia
Haolu Sun, Yi-wan Wu, He-ge Bian, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 67
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators
Ingrid Fatima Zattoni, Letícia Carani Delabio, Júlia de Paula Dutra, et al.
European Journal of Medicinal Chemistry (2022) Vol. 237, pp. 114346-114346
Closed Access | Times Cited: 44
Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review
Robert Terkeltaub
Drugs (2023) Vol. 83, Iss. 16, pp. 1501-1521
Closed Access | Times Cited: 35
Emerging Strategies to Overcome Chemoresistance: Structural Insights and Therapeutic Targeting of Multidrug Resistance-Linked ATP-Binding Cassette Transporters
Raghavendra Sashi Krishna Nagampalli, Gangadhar P. Vadla, Eswar Kumar Nadendla
International Journal of Translational Medicine (2025) Vol. 5, Iss. 1, pp. 6-6
Open Access | Times Cited: 1
BCRP/ABCG2 and high-alert medications: Biochemical, pharmacokinetic, pharmacogenetic, and clinical implications
Daiki Hira, Tomohiro Terada
Biochemical Pharmacology (2017) Vol. 147, pp. 201-210
Closed Access | Times Cited: 76
Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor
Tetsuya Taniguchi, Naoki Ashizawa, Koji Matsumoto, et al.
Journal of Pharmacology and Experimental Therapeutics (2019) Vol. 371, Iss. 1, pp. 162-170
Open Access | Times Cited: 76
Investigational drugs for hyperuricemia, an update on recent developments
Tristan Pascart, Pascal Richette
Expert Opinion on Investigational Drugs (2018) Vol. 27, Iss. 5, pp. 437-444
Closed Access | Times Cited: 72
ADMET evaluation in drug discovery. 20. Prediction of breast cancer resistance protein inhibition through machine learning
Dejun Jiang, Tailong Lei, Zhe Wang, et al.
Journal of Cheminformatics (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 70
Positron Emission Tomography Imaging of [11C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin A
Sarah Billington, Steven C. Shoner, Scott D. Lee, et al.
Clinical Pharmacology & Therapeutics (2019) Vol. 106, Iss. 5, pp. 1056-1066
Open Access | Times Cited: 58
Functional Characterization of Clinically-Relevant Rare Variants in ABCG2 Identified in a Gout and Hyperuricemia Cohort
Yu Toyoda, Andrea Mančíková, Vladimír Krylov, et al.
Cells (2019) Vol. 8, Iss. 4, pp. 363-363
Open Access | Times Cited: 57
Perspectives on drug repurposing to overcome cancer multidrug resistance mediated by ABCB1 and ABCG2
Chung‐Pu Wu, Sung-Han Hsiao, Yu‐Shan Wu
Drug Resistance Updates (2023) Vol. 71, pp. 101011-101011
Closed Access | Times Cited: 22
Pharmacological evaluation of a novel skeleton compound isobavachin (4′,7-dihydroxy-8-prenylflavanone) as a hypouricemic agent: Dual actions of URAT1/GLUT9 and xanthine oxidase inhibitory activity
Zean Zhao, Jian Luo, Hui Liao, et al.
Bioorganic Chemistry (2023) Vol. 133, pp. 106405-106405
Closed Access | Times Cited: 21
A Possible Therapeutic Application of the Selective Inhibitor of Urate Transporter 1, Dotinurad, for Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular Disease
Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
Cells (2024) Vol. 13, Iss. 5, pp. 450-450
Open Access | Times Cited: 7
Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib
Wenan Qiang, Orlando Antelope, Matthew S. Zabriskie, et al.
Leukemia (2017) Vol. 31, Iss. 12, pp. 2844-2847
Open Access | Times Cited: 61
Identification of ABCG2 as an Exporter of Uremic Toxin Indoxyl Sulfate in Mice and as a Crucial Factor Influencing CKD Progression
Tappei Takada, Takehito Yamamoto, Hirotaka Matsuo, et al.
Scientific Reports (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 56
The genetics of gout: towards personalised medicine?
Nicola Dalbeth, Lisa K. Stamp, Tony R. Merriman
BMC Medicine (2017) Vol. 15, Iss. 1
Open Access | Times Cited: 55
Multiple common and rare variants ofABCG2cause gout
Toshihide Higashino, Tappei Takada, Hirofumi Nakaoka, et al.
RMD Open (2017) Vol. 3, Iss. 2, pp. e000464-e000464
Open Access | Times Cited: 54
Targeting inflammatory cytokine storm to fight against COVID-19 associated severe complications
Rishabh Hirawat, Mohd Aslam Saifi, Chandraiah Godugu
Life Sciences (2020) Vol. 267, pp. 118923-118923
Open Access | Times Cited: 45
CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia
Zean Zhao, Jiang Yu, Yanyu Chen, et al.
Acta Pharmacologica Sinica (2021) Vol. 43, Iss. 1, pp. 121-132
Open Access | Times Cited: 34
Page 1 - Next Page

Scroll to top